Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00090090
Status:
COMPLETED
Last Update Posted:
2008-01-15
First Post:
2004-08-24
Brief Title:
Elsamitrucin SPI 28090 for Relapsed or Refractory Non-Hodgkins Lymphoma
Sponsor:
Spectrum Pharmaceuticals Inc
Organization:
Spectrum Pharmaceuticals Inc
Study Overview
Official Title:
A Multi-Center Open-Label Non-Randomized Phase II Study of Elsamitrucin SPI 28090 In Patients With Relapsed or Refractory Non-Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkins lymphoma NHL To determine if elsamitrucin is efficacious in a particular pathologic NHL subtypes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None